Tarrytown, New York-based Regeneron Pharmaceuticals, Inc. (REGN) discovers, invents, develops, manufactures, and ...

Longleaf Partners, managed by Southeastern Asset Management, released its “Partners Fund” second-quarter 2025 investor letter ...

Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) is one of the Best Extremely Profitable Stocks to Buy Right Now . On July 22, ...

Buying $1000 In REGN: If an investor had bought $1000 of REGN stock 20 years ago, it would be worth $57,109.53 today based on a price of $563.10 for REGN at the time of writing.

A stock with low volatility can be reassuring, but it doesn’t always mean strong long-term performance. Investors who ...

Regeneron Pharmaceuticals sees strength in Dupixent, oncology gains, and major buybacks despite setbacks. Find out why REGN stock is upgraded to buy.

Shares of Regeneron Pharmaceuticals Inc. REGN slid 1.35% to $564.64 Thursday, on what proved to be an all-around mixed trading session for the stock market, with the S&P 500 Index SPX rising 0.07% to ...

Regeneron Pharmaceuticals (REGN) has been in a persistent downtrend for over 280 days. The stock is currently in the 10th Phase of its 18-Phase Adhishthana Cycle, our proprietary cyclical framework.

Is Regeneron stock a buy now? Per the terms of the agreement, Regeneron will pay an upfront amount of $80 million, with potential clinical and regulatory milestones of up to $1.93 billion, in ...

Regeneron will announce Q2 2025 results on August 1, 2025, and host a conference call at 8:30 AM ET. Regeneron Pharmaceuticals, Inc. announced that it will disclose its second quarter 2025 ...

Shares of Regeneron Pharmaceuticals Inc. REGN shed 1.24% to $522.68 Monday, on what proved to be an all-around positive trading session for the stock market, with the S&P 500 Index SPX rising 0.94 ...